142 related articles for article (PubMed ID: 35277376)
1. Elevated circulating memory T cells precede immunotherapy toxicities in melanoma.
Bello E; Dougan M
Trends Cancer; 2022 May; 8(5):347-349. PubMed ID: 35277376
[TBL] [Abstract][Full Text] [Related]
2. Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications.
Schilling HL; Glehr G; Kapinsky M; Ahrens N; Riquelme P; Cordero L; Bitterer F; Schlitt HJ; Geissler EK; Haferkamp S; Hutchinson JA; Kronenberg K
Front Immunol; 2021; 12():765644. PubMed ID: 34868015
[TBL] [Abstract][Full Text] [Related]
3. Tissue-resident memory T cells in immunotherapy and immune-related adverse events by immune checkpoint inhibitor.
Xiong H; Shen Z
Int J Cancer; 2024 Jul; 155(2):193-202. PubMed ID: 38554117
[TBL] [Abstract][Full Text] [Related]
4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
[TBL] [Abstract][Full Text] [Related]
6. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?
Reschke R; Deitert B; Enk AH; Hassel JC
Front Immunol; 2024; 15():1385781. PubMed ID: 38562921
[TBL] [Abstract][Full Text] [Related]
7. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
Lozano AX; Chaudhuri AA; Nene A; Bacchiocchi A; Earland N; Vesely MD; Usmani A; Turner BE; Steen CB; Luca BA; Badri T; Gulati GS; Vahid MR; Khameneh F; Harris PK; Chen DY; Dhodapkar K; Sznol M; Halaban R; Newman AM
Nat Med; 2022 Feb; 28(2):353-362. PubMed ID: 35027754
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
9. Interferon-Gamma-Producing CD8
Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.
Park BC; Stone CA; Dewan AK; Johnson DB
Immunol Allergy Clin North Am; 2022 May; 42(2):285-305. PubMed ID: 35469619
[TBL] [Abstract][Full Text] [Related]
11. Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma.
Asdourian MS; Otto TS; Jacoby TV; Shah N; Thompson LL; Blum SM; Reynolds KL; Semenov YR; Lawrence DP; Sullivan RJ; Boland GM; Villani AC; Chen ST
J Am Acad Dermatol; 2022 Nov; 87(5):1147-1149. PubMed ID: 35192899
[No Abstract] [Full Text] [Related]
12. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
Front Immunol; 2021; 12():685370. PubMed ID: 34220837
[TBL] [Abstract][Full Text] [Related]
13. Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors.
Gulati N; Celen A; Johannet P; Mehnert JM; Weber J; Krogsgaard M; Osman I; Zhong J
Cancer Med; 2021 Nov; 10(21):7457-7465. PubMed ID: 34647433
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in melanoma.
Carlino MS; Larkin J; Long GV
Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor Toxicities.
Marin-Acevedo JA; Chirila RM; Dronca RS
Mayo Clin Proc; 2019 Jul; 94(7):1321-1329. PubMed ID: 31272574
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Luoma AM; Suo S; Williams HL; Sharova T; Sullivan K; Manos M; Bowling P; Hodi FS; Rahma O; Sullivan RJ; Boland GM; Nowak JA; Dougan SK; Dougan M; Yuan GC; Wucherpfennig KW
Cell; 2020 Aug; 182(3):655-671.e22. PubMed ID: 32603654
[TBL] [Abstract][Full Text] [Related]
17. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
18. Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
Gkoufa A; Gogas H; Diamantopoulos PT; Ziogas DC; Psichogiou M
J Immunother; 2020 Sep; 43(7):224-229. PubMed ID: 32554976
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy and Gastrointestinal Toxicities.
Simand PF; Baudoux N; Kössler T
Praxis (Bern 1994); 2023; 112(3):172-177. PubMed ID: 36855888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
